Leukemia


Gilteritinib Approved for Advanced Acute Myeloid Leukemia (AML) with a FLT3 Mutation (11-29-2018)

The U.S. Food and Drug Administration approved Xospata (gilteritinib) for treatment of adult patients who have recurrent or refractory acute myeloid leukemia (AML) with a FLT3 mutation. About Xospata Xospata has demonstrated inhibitory activity against... Continue Reading

FDA Approves Venclexta Combination for AML in Adults (11-26-2018)

The Food and Drug Administration granted accelerated approval to Venclexta (venetoclax) in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years... Continue Reading

duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (09-25-2018)

The Food and Drug Administration granted regular approval to duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. In... Continue Reading

Tibsovo Approved for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and an IGH1 Mutation (07-23-2018)

Tibsovo® (ivosidenib) has been granted approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation... Continue Reading

FDA Approves Venetoclax for Chronic and Small Lymphocytic Leukemia/Lymphoma With or Without 17 p Deletion, (06-25-2018)

The Food and Drug Administration granted regular approval to Venclexta (venetoclax) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Approval... Continue Reading

Venclexta Significantly Reduces Cancer Progression in Chronic Lymphocytic Leukemia (03-22-2018)

CancerConnect News: Venclexta (venetoclax) plus Rituxan (rituximab) significantly reduces the risk of cancer progression or death at two years, compared with Treanda (bendustamine) plus Rituxan in the treatment of chronic lymphocytic leukemia that has... Continue Reading

CRISPR Enhances Cancer Immunotherapy (03-14-2018)

Gene editing expands reach of therapeutic T cells, in mice CancerConnect News: Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient’s own immune cells —... Continue Reading

U.S. FDA Approves Trisenox® Injection for First Line Treatment of Acute Promyelocytic Leukemia (01-31-2018)

CancerConnect News: the U.S. Food and Drug Administration (FDA) has approved the use of Trisenox® (arsenic trioxide) injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL)... Continue Reading

FDA Grants Accelerated Approval to Bosulif for Treatment of Newly-Diagnosed Chronic Myelogenous Leukemia (01-14-2018)

CancerConnect News: On December 19, 2017, the Food and Drug Administration granted accelerated approval to bosutinib Bosulif (bosutinib) for treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous... Continue Reading

Pass it On: It’s Leukemia National Awareness Month (09-19-2017)

Leukemia and lymphoma are both hematologic malignancies, meaning that they involve the blood or bone marrow. The American Cancer Society (ACS) estimates that there will be 60,140 new cases of leukemia and 24,400 deaths in 2016. For lymphoma, the ACS estimates... Continue Reading

Next Page »